Popular Searches:

Your Previous Searches:

Recently Visited Pages:

Home
Equities
Equities
View All Equities
Equities by Sector

Consumer

Energy & Resources

Financials

Healthcare

Industrials

Investment Companies

Metals & Mining

Real Estate

TMT

IRLAB Therapeutics

MCap

SEK653m

Last close

SEK14.10

▲ 1.50 (11.90%)

VolitionRx

MCap

USD51m

Last close

USD0.60

▲ 0.05 (9.82%)

Portobello SpA

MCap

EUR12m

Last close

EUR2.38

▲ 0.20 (9.17%)
Sectors
Sectors
Thematics
Thematics
View All Thematics

Latest
Audiovisual
Audiovisual
View All Audiovisual

Latest

Events
About Edison
About Edison
About Edison

Careers

“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”

Financial Director
Equity Research
Investor Relations
Contact us

BioPorto – executive interview

BioPorto – executive interview

BioPorto Diagnostics — 2 videos in collection

More on this equity

BioPorto is a Denmark-based in vitro diagnostics company that uses antibody and assay expertise to transform novel research tools into clinically actionable biomarkers. The company’s portfolio includes The NGAL Test for the prediction of acute kidney injury and an extensive antibody library.

In this video, Peter Eriksen, BioPorto’s chief executive officer, highlights the company’s year-end earnings results and discusses the status of its resubmission timeline to the FDA for pediatric The NGAL Test. He also provides an update on the corporate outlook for 2021 and reviews a new vision for the product portfolio with a focus on expanding BioPorto’s proprietary gRAD technology.

< Previous

Next >

You may also be interested in these:

Healthcare

03.02.21

Bioporto – Edison Open House interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free